6 min read
Katalin Karikó is a biochemist originally from Hungary detection about the substance MRNA Fight diseases that pave the way for Development of Antikovid vaccines by the Moderna and Pfizer / BioNTech laboratories, Your findings could make it possible to fight this pandemic.
The Researcher and biologist Hungarian spoke in an interview for the newspaper The countryabout his beginnings in the biology career and how it was his path to achieve the discoveries that large pharmaceutical companies are making today for the manufacture of cans against the coronavirus.
“I was a happy girl. My father was a butcher and I enjoyed watching him work, watching the bowels, the hearts of animals, maybe that’s where my scientific streak came from, ”says Karikó, who was born in 1955 in the city of Kisújszállás, about 100 kilometers from the capital Hungary, Budapest.
After studying the career of Biology in Hungary, he went to the USA to do his PhD in 1985, but he never returned. He points out that he wanted to go to Spain with Luis Carrasco’s group, interested in his work, as well as France, but that communist Hungary “made things difficult”.
The doses against the coronavirus developed from Pfizer / BioNTech and Modern they use Messenger RNA to stimulate that it is the same cells in the individual that produce a reaction against an external agent that threatens to enter the body. This molecule is responsible for penetrating the cell nucleus and interpreting the body’s demands in order to adapt to them.
Even though I am a Technology that appears to be effective against coronavirus, Kariko Every time he sought funding for his development, he received several rejections for his idea. “Now everyone understands, but before that it was about changing that DNA Correcting diseases until they realized that mutations can be caused that can lead to death, ”the biochemist told this medium.
The specialist stated that after long years of work she was not used to care and support, but assures that this shows why science should be supported on many levels.
Learn more: Thanks to mRNA technology, Moderna developed a Covid-19 vaccine in just two days
Lack of support for your idea in the 1990s
KarikoThe 65-year-old biochemist spent most of the 1990s filing compensation claims to fund her research “Messenger ribonucleic acid”, genetic molecules that tell cells which proteins to produce essential to keep the body alive and healthy.
As such, the idea was good, but not “fashionable”. They wanted to use a fragile and short-lived molecule to cure disease and invariably prevent infection. He RNA is a Basic molecule for life, since it is the messenger that is responsible for penetrating the nucleus and reading the genetic information that DNA and develop the formula for the production of all the proteins required to perform all activities.
What the biochemistry wanted was to use the same patient’s cells to make the protein that would cure them by delivering a tiny message from RNA. “Everyone understands it now, but not then,” says the expert.
In the late 1980s, much of the scientific community focused on the use of DNA with the aim of gene therapy. The Hungarian specialist, however, considered this to be very promising MRNAThis is because most diseases are not hereditary and do not require solutions that permanently alter our genetics.
In particular, he faced a major problem, as in animal experiments in MRNA The synthetic compound triggered a massive inflammatory response when the immune system found an invader and rushed to fight it.
It was able to overcome this problem together with the scientist Drew Weissmanwhen they both discovered that one of the Four building blocks of synthetic mRNA failed and were able to solve this problem by switching to a modified version.
They then published an article on progress in 2005. In 2015 they found a new way to care MRNA to mice that have a layer of fat called “Lipid nanoparticles” This prevents the mRNA from being broken down and helps place it in the correct part of the cells.
How did Karikó come to BioNTech?
In 2010 a A group of American researchers founded a company that acquired the rights to Karikó’s patents and Weissman. Is known as an acronym for “Modified RNA”: ModerRNA. Three years later, after 40 years of working almost anonymously, Kariko was booked by BioNTech, Company in which she currently serves as Vice President.
“I felt it was time to change and I thought I could take the position to make sure things are going in the right direction,” he says. Kariko. Vaccinations Modern and BioNTech, developed together with Pfizer, have guaranteed an efficiency of at least 94 percent.
Learn more: Pfizer announced that its vaccine is 95% effective in older adults too